Educational information only. This site does not provide medical advice. Read full disclaimer
    PepTracker Pro
    Open the App
    Research-only content. This page is for educational purposes and does not constitute medical advice. Read full disclaimer →

    Pinealon

    Low Evidence

    A short bioregulatory peptide studied for neuroprotective effects and cognitive support in aging.

    AliasesEDR peptide+1 more
    EvidenceLow Evidence
    Last Updated 2026-05-27
    Reading Time 2 min

    What It Is

    Pinealon (Glu-Asp-Arg / EDR) is a synthetic tripeptide developed by the Khavinson Peptide Institute in St. Petersburg, Russia, designed to mimic the regulatory effects of pineal gland extracts on circadian function and neuroprotection. It belongs to the class of bioregulatory peptides — short synthetic peptides based on the theory that specific di- and tripeptide sequences can interact with DNA promoter regions to regulate gene expression. In preclinical studies, pinealon has been shown to increase melatonin synthesis in pinealocyte cultures, modulate serotonin metabolism, and demonstrate neuroprotective effects against oxidative stress-induced neuronal damage. Cell culture studies have reported that pinealon reduces neuronal apoptosis and improves cell viability under oxidative stress conditions. The bioregulatory peptide theory, while supported by in vitro data from the Khavinson group, has not been independently validated in large-scale studies, and the proposed mechanism of direct DNA interaction by short peptides remains controversial in the broader scientific community. No human clinical trials with rigorous placebo-controlled methodology have been published for pinealon. It is not FDA-approved and remains strictly a research compound.

    Also known as: EDR peptide, Glu-Asp-Arg

    Why Researchers Study It

    Pinealon exemplifies the Khavinson hypothesis that short peptides can selectively restore organ function when derived from that organ's tissue. As a pineal-origin peptide, it is studied for potential regulatory effects on circadian rhythms, melatonin production, and neuroprotection via epigenetic mechanisms.

    Proposed Mechanisms

    • Proposed DNA-binding peptide that modulates gene expression in brain and pineal tissue
    • May restore age-related decline in pineal function and melatonin signaling
    • Neuroprotective effects possibly mediated through antioxidant gene upregulation
    • Part of the bioregulatory peptide model alongside Thymalin and Epithalon

    Evidence Snapshot

    Low Evidence
    Low
    Medium
    High

    Commonly Discussed Benefits

    Safety & Cautions

    • Research primarily from Russian laboratories
    • Limited independent replication
    • No Western clinical trials
    • Not FDA-approved

    Comparisons

    See how Pinealon compares to related peptides:

    Calculator Tools

    Use our research tools to explore dosing and reconstitution data:

    Citations

    1. [1] Khavinson VK. et al. — Short peptides and gene expression. Bull Exp Biol Med. 2006 PubMed

    Continue Your Research

    Track your research notes and set reminders in the companion app.

    Related Peptides

    Semax

    Medium Evidence

    A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.

    Epithalon

    Low Evidence

    A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.

    Cerebrolysin

    Medium Evidence

    A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.

    Thymalin

    Low Evidence

    A thymic peptide preparation studied for immune system rejuvenation and age-related immune decline.